FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business ApplicationsTORONTO, ON / ACCESSWIRE / June 13, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (\"FSD Pharma\"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it entered into an exclusive option agreement with the University of Southern California (USC) to evaluate dietary supplement technology for commercialization. The option agreement, signed June 11, 2024, allows FSD Pharma to exclusively evaluate the novel technology for a 6-month term. At the end of this term, FSD Pharma will have the option to either extend it for an additional 6 months or to sign an exclusive license for the technology with USC. This novel technology is being evaluated for the potential to further increase the effectiveness of certain ingredients currently present in unbuzzd™. unbuzzd™ is a scientifically formulated blend of vitamins, minerals, and herbs engineered to expedite alcohol metabolism, facilitate faster recovery from alcohol consumption, and simultaneously enhance mental alertness to those individuals who consume it. FSD Pharma has partnered with Celly Nutrition, being led by beverage industry leaders Gerry David formerly CEO of Celsius Holdings, Inc. and John Duffy formerly of The Coca-Cola Company, to launch unbuzzd™ this summer.\"This partnership with FSD Pharma underscores USC's longstanding commitment to fostering innovation and translating scientific research into practical solutions that benefit society,\" said Dr. Erin Overstreet, executive director at the USC Stevens Center for Innovation. \"We are excited to be working with FSD Pharma, leveraging their expertise in the biopharmaceutical industry, exploring the potential of this novel technology, and enhancing the portfolio of dietary supplement products. Together, we aim to bring forward new advancements that contribute to positive health and well-being for all.\"\"We are thrilled to sign the option agreement with USC. We are looking forward to evaluating this novel technology that has the potential to both further enhance the effectiveness of unbuzz...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B